Testicular Yolk Sac Tumor Overview

Save information for later
Sign Up

Learn About Testicular Yolk Sac Tumor

What is the definition of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor is a subtype of testicular cancer that most commonly occurs in the testicles of young and middle-age men. While the exact cause is not well understood, some risk factors have been determined, such as undescended testicle, abnormal testicle development, smoking, exposure to some chemicals, family history of testicular cancer, HIV infection, and Down syndrome.
What are the symptoms of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor may have no symptoms or appear as a painless mass in the testes. If symptoms occur, they may include discomfort or pain, or a sense of heaviness in the scrotum, lower back of abdominal pain, an enlarged testicle, or an overgrowth of male breast tissue. The cancer may spread to other parts of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Testicular Yolk Sac Tumor?
Treatment for testicular yolk sac cancer depends on how far the cancer has spread and includes surgery (removal of the testicle), radiation therapy, and chemotherapy. Testicular yolk sac cancer is highly treatable and has a high rate of success. Testicular cancer can be detected early by performing a monthly testicular self-examination.
Who are the top Testicular Yolk Sac Tumor Local Doctors?
Distinguished in Testicular Yolk Sac Tumor
Dr. Andrew Berchuck
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Testicular Yolk Sac Tumor
Dr. Andrew Berchuck
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Berchuck is a Gynecologic Oncologist and an Oncologist in Durham, North Carolina. Dr. Berchuck is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Tubal Ligation, and Oophorectomy. Dr. Berchuck is currently accepting new patients.

Distinguished in Testicular Yolk Sac Tumor
Dr. Angeles A. Secord
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Testicular Yolk Sac Tumor
Dr. Angeles A. Secord
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angeles Secord is a Gynecologic Oncologist and an Oncologist in Durham, North Carolina. Dr. Secord is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Intrauterine Device Insertion. Dr. Secord is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Testicular Yolk Sac Tumor
Dr. Megan M. Petersen
Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Megan M. Petersen
Oncology

Intermountain Health West End Clinic Gynecologic Oncology

602 Henry Chapple Street, 
Billings, MT 
406-901-2440
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Megan Petersen is an Oncologist in Billings, Montana. Dr. Petersen has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Cervical Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Colonoscopy, and Bladder Reconstruction. Dr. Petersen is currently accepting new patients.

View All Doctors
What are the latest Testicular Yolk Sac Tumor Clinical Trials?
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-pr...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Who is this study for: Patients with localized non-germinomatous central nervous system germ cell tumor
Enrollment Status: Recruiting
Publish Date: January 07, 2026
Intervention Type: Drug, Procedure, Biological, Radiation, Other
Study Drugs: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Mesna, Pegfilgrastim, Thiotepa
Study Phase: Phase 2

Summary: This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish...

View All Clinical Trials